Skip to main content
Log in

Risk: Benefit Profile of Etanercept in Elderly Patients with Rheumatoid Arthritis, Ankylosing Spondylitis or Psoriatic Arthritis

Drugs & Aging Aims and scope Submit manuscript

Abstract

Rheumatoid arthritis (RA), ankylosing spondylitis (AS) and psoriatic arthritis (PsA) are commonly thought of as inflammatory diseases that affect younger individuals. Although the initial presentation of these diseases is commonly in a patient’s twenties or thirties, they usually persist for the duration of the patient’s life. In addition, up to one-third of patients with RA have disease onset after 60 years of age. Older patients with any of these three diseases are more likely to have more severe disease with significant functional decline. They are also more likely to have co-morbid diseases and use concomitant medications than patients who are younger.

In patients with RA, AS or PsA, the introduction of anti-tumour necrosis factor (TNF)-α therapies such as etanercept, infliximab and adalimumab has had a significant impact in ameliorating the signs and symptoms of disease, improving patient function and inhibiting radiographic progression. Anti-TNFα therapies now have well recognised safety profiles that have been demonstrated in the usual clinical trial populations for these diseases, but such populations under-represent patients ≥65 years of age.

This review explores the information currently available regarding patients aged ≥65 years treated with anti-TNFα therapies for RA, AS or PsA, focusing on etanercept in RA because of a lack of data for other therapies and conditions. The analyses conducted show that there is similar efficacy in the treatment of RA in patients <65 years old and those ≥65 years of age. Although there are some differences in the adverse events noted in these two age groups, it appears as though treatment of patients ≥65 years of age, compared with age-matched controls, is not dissimilar to treatment of patients <65 years of age compared with their age-matched controls. Only by understanding the risks and benefits of therapy in the older age group can a true risk: benefit profile for etanercept, and ultimately other anti-TNFα therapies, be determined by the practising physician and the patient.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III
Table IV
Table V

References

  1. Nesher G, Moore TL. Rheumatoid arthritis in the aged: incidence and optimal management. Drugs Aging 1993; 3(6): 487–501

    Article  PubMed  CAS  Google Scholar 

  2. Lawrence RC, Heimick CG, Arnett FC, et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 1998; 41(5): 778–99

    Article  PubMed  CAS  Google Scholar 

  3. Gabriel SE, Crowson CS, O’Fallon WM. The epidemiology of rheumatoid arthritis in Rochester, Minnesota, 1955–1985. Arthritis Rheum 1999; 42(3): 415–20

    Article  PubMed  CAS  Google Scholar 

  4. Rasch EK, Hirsch R, Paulose-Ram R, et al. Prevalence of rheumatoid arthritis in persons 60 years of age and older in the United States: effect of different methods of case classification. Arthritis Rheum 2003; 48(4): 917–26

    Article  PubMed  Google Scholar 

  5. Ehrlich GE, Katz WA, Cohen SH. Rheumatoid arthritis in the aged. Geriatrics 1970; 25(2): 103–13

    PubMed  CAS  Google Scholar 

  6. Linos A, Worthington JW, O’Fallon WM, et al. The epidemiology of rheumatoid arthritis in Rochester, Minnesota: a study of incidence, prevalence, and mortality. Am J Epidemiol 1980; 111(1): 87–98

    PubMed  CAS  Google Scholar 

  7. Nesher G, Moore TL, Zuckner J. Rheumatoid arthritis in the elderly. J Am Geriatr Soc 1991; 39(3): 284–94

    PubMed  CAS  Google Scholar 

  8. Symmons DP, Barrett EM, Bankhead CR, et al. The incidence of rheumatoid arthritis in the United Kingdom: results from the Norfolk Arthritis Register. Br J Rheumatol 1994; 33(8): 735–9

    Article  PubMed  CAS  Google Scholar 

  9. Terkeltaub R, Esdaile J, Decary F, et al. A clinical study of older age rheumatoid arthritis with comparison to a younger onset group. J Rheumatol 1983; 10(3): 418–24

    PubMed  CAS  Google Scholar 

  10. Papadopoulos IA, Katsimbri P, Alamanos Y, et al. Early rheumatoid arthritis patients: relationship of age. Rheumatol Int 2003; 23(2): 70–4

    PubMed  Google Scholar 

  11. Braun J, Bollow M, Remlinger G, et al. Prevalence of spondy-larthropathies in HLA-B27 positive and negative blood donors. Arthritis Rheum 1998; 41(1): 58–67

    Article  PubMed  CAS  Google Scholar 

  12. Rudwaleit M, Khan MA, Sieper J. The challenge of diagnosis and classification in early ankylosing spondylitis. Arthritis Rheum 2005; 52(4): 1000–8

    Article  PubMed  Google Scholar 

  13. Olivieri I, van Tubergen A, Salvarani C, et al. Seronegative spondyloarthritides. Best Pract Res Clin Rheumatol 2002; 16(5): 723–39

    Article  PubMed  Google Scholar 

  14. Feldtkeller E, Khan MA, van der Heijde D, et al. Age at disease onset and diagnosis delay in HLA-B27 negative vs. positive patients with ankylosing spondylitis. Rheumatol Int 2003; 23(2): 61–6

    PubMed  Google Scholar 

  15. Gladman DD. Psoriatic arthritis. In: Isenberg DA, editor. Oxford textbook of rheumatology. 3rd ed. Oxford (UK): Oxford University Press, 2004: 829–44

    Google Scholar 

  16. Punzi L, Pianon M, Rossini P, et al. Clinical and laboratory manifestations of elderly onset psoriatic arthritis: a comparison with younger onset disease. Ann Rheum Dis 1999; 58(4): 226–9

    Article  PubMed  CAS  Google Scholar 

  17. Caplanne D, Tubach F, Le Parc JM. Late onset spondylar-thropathy: clinical and biological comparison with early onset subjects. Ann Rheum Dis 1997; 56(3): 178–9

    Article  Google Scholar 

  18. Centers for Disease Control and Prevention. Impact of arthritis and other rheumatic conditions on the health-care system-United States, 1997. JAMA 1999; 281(23): 2177–8

    Article  Google Scholar 

  19. Badley EM, Tennant A. Impact of disablement due to rheumatic disorders in a British population: estimates of severity and prevalence from the Calderdale Rheumatic Disablement Survey. Ann Rheum Dis 1993; 52(1): 6–13

    Article  PubMed  CAS  Google Scholar 

  20. Kavanaugh AF. Rheumatoid arthritis in the elderly: is it a different disease? Am J Med 1997; 103(6A): 40S–8S

    Article  PubMed  CAS  Google Scholar 

  21. Jakobsson U, Hallberg IR. Pain and quality of life among older people with rheumatoid arthritis and/or osteoarthritis: a literature review. J Clin Nurs 2002; 11(4): 430–43

    Article  PubMed  Google Scholar 

  22. Young A, Dixey J, Kulinskaya E, et al. Which patients stop working because of rheumatoid arthritis? Results of five years’ follow up in 732 patients from the Early RA Study (ERAS). Ann Rheum Dis 2002; 61(4): 335–40

    Article  PubMed  CAS  Google Scholar 

  23. Young A, Dixey J, Cox N, et al. How does functional disability in early rheumatoid arthritis (RA) affect patients and their lives? Results of 5 years of follow-up in 732 patients from the Early RA Study (ERAS). Rheumatology (Oxford) 2000; 39(6): 603–11

    Article  CAS  Google Scholar 

  24. Yelin E, Wanke LA. An assessment of the annual and long-term direct costs of rheumatoid arthritis: the impact of poor function and functional decline. Arthritis Rheum 1999; 42(6): 1209–18

    Article  PubMed  CAS  Google Scholar 

  25. Birnbaum HG, Barton M, Greenberg PE, et al. Direct and indirect costs of rheumatoid arthritis to an employer. J Occup Environ Med 2000; 42(6): 588–96

    Article  PubMed  CAS  Google Scholar 

  26. Albers JM, Kuper HH, Van Riel PL, et al. Socio-economic consequences of rheumatoid arthritis in the first years of the disease. Rheumatology (Oxford) 1999; 38(5): 423–30

    Article  CAS  Google Scholar 

  27. Dagfinrud H, Kjeken I, Mowinckel P, et al. Impact of functional impairment in ankylosing spondylitis: impairment, activity limitation, and participation restrictions. J Rheumatol 2005; 32(3): 516–23

    PubMed  Google Scholar 

  28. DaCosta D, Dritsa M, Ring A, et al. Mental health status and leisure-time physical activity contribute to fatigue intensity in patients with spondylarthropathy. Arthritis Rheum 2004; 51(6): 1004–8

    Article  Google Scholar 

  29. McKenna SP, Doward L. Functional disability and quality of life in patients with ankylosing spondylitis. Rheumatol Int 2004; 24(1): 57–8

    Article  PubMed  Google Scholar 

  30. Bostan EE, Borman P, Bodur H, et al. Functional disability and quality of life in patients with ankylosing spondylitis. Rheumatol Int 2003; 23(3): 121–6

    PubMed  Google Scholar 

  31. Khan MA. Update on spondyloarthropathies. Ann Intern Med 2002; 136(12): 896–907

    PubMed  Google Scholar 

  32. Sieper J, Braun J, Rudwaleit M, et al. Ankylosing spondylitis: an overview. Ann Rheum Dis 2002; 61Suppl. 3: iii8–iiil8

    PubMed  Google Scholar 

  33. Mclntosh E. The cost of rheumatoid arthritis. Br J Rheumatol 1996; 35(8): 781–90

    Article  Google Scholar 

  34. Dahl SL, Samuelson CO, Williams HJ, et al. Second-line antirheumatic drugs in the elderly with rheumatoid arthritis: a post hoc analysis of three controlled trials. Pharmacotherapy 1990; 10(2): 79–84

    PubMed  CAS  Google Scholar 

  35. Rochon PA, Fortin PR, Dear KB, et al. Reporting of age data in clinical trials of arthritis: deficiencies and solutions. Arch Intern Med 1993; 153(2): 243–8

    Article  PubMed  CAS  Google Scholar 

  36. Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000; 343(22): 1586–93

    Article  PubMed  CAS  Google Scholar 

  37. Breedveld F, Weisman M, Kavanaugh A, et al. The PREMIER study: combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in metho-trexate-naive patients with early, aggressive rheumatoid arthritis. Arthritis Rheum 2006; 54(1): 26–37

    Article  PubMed  CAS  Google Scholar 

  38. St Clair EW, van der Heijde DM, Smolen JS, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 2004; 50(11): 3432–43

    Article  PubMed  CAS  Google Scholar 

  39. Keystone EC, Kavanaugh AF, Sharp JT, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 2004; 50(5): 1400–11

    Article  PubMed  CAS  Google Scholar 

  40. Lipsky PE, van der Heijde DM, St Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis: Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000; 343(22): 1594–602

    Article  PubMed  CAS  Google Scholar 

  41. Maini R, St Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial: ATTRACT Study Group. Lancet 1999; 354(9194): 1932–9

    Article  PubMed  CAS  Google Scholar 

  42. Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999; 340(4): 253–9

    Article  PubMed  CAS  Google Scholar 

  43. Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003; 48(1): 35–45

    Article  PubMed  CAS  Google Scholar 

  44. Tutuncu Z, Reed G, Kremer J, et al. Do patients with older onset rheumatoid arthritis receive less aggressive treatment than younger patients. Ann Rheum Dis 2006; 65(9): 1226–9

    Article  PubMed  CAS  Google Scholar 

  45. Genovese MC, Bathon JM, Fleischmann RM, et al. Long term safety, efficacy, and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritis. J Rheu-matol 2005; 32(7): 1232–42

    CAS  Google Scholar 

  46. Fries JF, Spitz PW, Young DY. The dimensions of health outcomes: the Health Assessment Questionnaire, disability and pain scales. J Rheumatol 1982; 9(5): 789–93

    PubMed  CAS  Google Scholar 

  47. van der Heijde DM, vant Hof M, Van Riel PL, et al. Development of a disease activity score based on judgment in clinical practice by rheumatologists. J Rheumatol 1993; 20(3): 579–81

    PubMed  Google Scholar 

  48. Fleischmann R, Baumgartner SW, Weisman MH, et al. Long term safety of etanercept in elderly subjects with rheumatic diseases. Ann Rheum Dis 2006; 65(3): 379–84

    Article  PubMed  CAS  Google Scholar 

  49. Bingham CO. The pathogenesis of rheumatoid arthritis: pivotal cytokines involved in bone degradation and inflammation. J Rheumatol 2002; 65 Suppl.: 3–9

    CAS  Google Scholar 

  50. Gratacos J, Collado A, Filella X, et al. Serum cytokines (IL-6, TNF-alpha, IL-1 beta and IFN-gamma) in ankylosing spondy-litis: a close correlation between IL-6 and disease activity and severity. Br J Rheumatol 1994; 33(10): 927–31

    Article  PubMed  CAS  Google Scholar 

  51. Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 1996; 14(10): 397–440

    Article  PubMed  CAS  Google Scholar 

  52. Grom AA, Murray KJ, Luyrink L, et al. Patterns of expression of tumor necrosis factor alpha, tumor necrosis factor beta, and their receptors in synovia of patients with juvenile rheumatoid arthritis and juvenile spondylarthropathy. Arthritis Rheum 1996; 39(10): 1703–10

    Article  PubMed  CAS  Google Scholar 

  53. Ritchlin C, Haas-Smith SA, Hicks D, et al. Patterns of cytokine production in psoriatic synovium. J Rheumatol 1998; 25(8): 1544–52

    PubMed  CAS  Google Scholar 

  54. Saxne T, Palladino MA Jr, Heinegard D, et al. Detection of tumor necrosis factor alpha but not tumor necrosis factor beta in rheumatoid arthritis synovial fluid and serum. Arthritis Rheum 1988; 31(8): 1041–5

    Article  PubMed  CAS  Google Scholar 

  55. van der Heijde DM, Landewe R, Keystone E, et al. Adalimumab (HUMIRA®) plus MTX prevents nearly all severe radiographic progression observed with methotrexate monotherapy in early, aggressive rheumatoid arthritis [abstract no. 207]. Arthritis Rheum 2005; 52Suppl. 9: 53

    Google Scholar 

  56. Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998; 41(9): 1552–63

    Article  PubMed  CAS  Google Scholar 

  57. Moreland LW, Baumgartner SW, Schiff MH, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997; 337(3): 141–7

    Article  PubMed  CAS  Google Scholar 

  58. Moreland LW, Schiff MH, Baumgartner SW, et al. Etanercept therapy in rheumatoid arthritis: a randomized, controlled trial. Ann Intern Med 1999; 130(6): 478–86

    PubMed  CAS  Google Scholar 

  59. van de Putte LB, Rau R, Breedveld FC, et al. Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study. Ann Rheum Dis 2003; 62(12): 1168–77

    Article  PubMed  Google Scholar 

  60. Baraliakos X, Listing J, Brandt J, et al. Influence of infliximab therapy on radiographie progression in patients with anky-losing spondylitis: results after 4 years of treatment [abstract no.1700]. Arthritis Rheum 2005; 52(9 Suppl.): S631

    Google Scholar 

  61. Baraliakos X, Listing J, Brandt J, et al. Less radiographie progression in patients with active ankylosing spondylitis after 2 years of anti-TNF therapy [abstract no.1701]. Arthritis Rheum 2005; 52(9 Suppl.): S631

    Google Scholar 

  62. Davis J Jr, Webb A, Lund S, et al. Results from an open-label extension study of etanercept in ankylosing spondylitis. Arthritis Rheum 2004; 51(2): 302–4

    Article  PubMed  Google Scholar 

  63. Davis JC Jr, van der Heijde HD, Braun J, et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 2003; 48(11): 3230–6

    Article  PubMed  CAS  Google Scholar 

  64. van der Heijde DM, Kivitz A, Schiff M, et al. Adalimumab therapy results in significant reduction of signs and symptoms in subjects with ankylosing spondylitis: the ATLAS trial [abstract no. 691]. Arthritis Rheum 2005; 52(9 Suppl.): 182

    Google Scholar 

  65. Antoni C, Krueger GG, de Vlam K, et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 2005; 64(8): 1150–7

    Article  PubMed  CAS  Google Scholar 

  66. Antoni CE, Kavanaugh A, Kirkham B, et al. Sustained benefits of infliximab therapy for dermatologie and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum 2005; 52(4): 1227–36

    Article  PubMed  CAS  Google Scholar 

  67. Kavanaugh A, Krueger GG, Birbara C, et al. Treatment with infliximab is associated with “major clinical response” in psoriatic arthritis patients treated with infliximab: analysis of two double-blind placebo controlled trials [abstract no. L18-18]. Arthritis Rheum 2005; 52(9 Suppl.): 18

    Google Scholar 

  68. Mease PJ, Goffe BS, Metz J, et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000; 356(9227): 385–90

    Article  PubMed  CAS  Google Scholar 

  69. Mease PJ, Ritchlin CT, Martin RW, et al. Pneumococcal vaccine response in psoriatic arthritis patients during treatment with etanercept. J Rheumatol 2004; 31(7): 1356–61

    PubMed  CAS  Google Scholar 

  70. Enbrel®: etanercept [product insert]. Thousand Oaks (CA): Immunex Corporation, 2003

  71. Genovese MC, Bathon JM, Martin RW, et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographie and clinical outcomes. Arthritis Rheum 2002; 46(6): 1443–50

    Article  PubMed  CAS  Google Scholar 

  72. Lovell DJ, Giannini EH, Reiff A, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis: Pediatrie Rheumatology Collaborative Study Group. N Engl J Med 2000; 342(11): 763–9

    Article  PubMed  CAS  Google Scholar 

  73. Lovell DJ, Giannini EH, Reiff A, et al. Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: interim results from an ongoing multicenter, open-label, extended-treatment trial. Arthritis Rheum 2003; 48(1): 218–26

    Article  PubMed  CAS  Google Scholar 

  74. Mease PJ. Etanercept, a TNF antagonist for treatment for psoriatic arthritis and psoriasis. Skin Therapy Lett 2003; 8(1): 1–4

    PubMed  CAS  Google Scholar 

  75. Smith CA, Farrah T, Goodwin RG. The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death. Cell 1994; 76(6): 959–62

    Article  PubMed  CAS  Google Scholar 

  76. Wooley PH, Dutcher J, Widmer MB, et al. Influence of a recombinant human soluble tumor necrosis factor receptor FC fusion protein on type II collagen-induced arthritis in mice. J Immunol 1993; 151(11): 6602–7

    PubMed  CAS  Google Scholar 

  77. Bathon JM, Fleischmann RM, Van Der HD, et al. Safety and efficacy of etanercept treatment in elderly subjects with rheumatoid arthritis. J Rheumatol 2006; 33(2): 234–43

    PubMed  CAS  Google Scholar 

  78. Fleischmann RM, Baumgartner SW, Tindall EA, et al. Response to etanercept (Enbrel) in elderly patients with rheumatoid arthritis: a retrospective analysis of clinical trial results. J Rheumatol 2003; 30(4): 691–6

    PubMed  CAS  Google Scholar 

  79. Klareskog L, van der Heijde DM, de Jager JP, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004; 363(9410): 675–81

    Article  PubMed  CAS  Google Scholar 

  80. Moreland LW, Cohen SB, Baumgartner SW, et al. Long-term safety and efficacy of etanercept in patients with rheumatoid arthritis. J Rheumatol 2001; 28(6): 1238–44

    PubMed  CAS  Google Scholar 

  81. Felson DT, Anderson JJ, Boers M, American College of Rheumatology, et al. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38(6): 727–35

    Article  PubMed  CAS  Google Scholar 

  82. Fleischmann R. Safety and efficacy of etanercept in the elderly. Aging Health 2006; 2(2): 189–97

    Article  CAS  Google Scholar 

  83. van der Heijde DM, Van Leeuwen MA, Van Riel PL, et al. Radiographic progression on radiographs of hands and feet during the first 3 years of rheumatoid arthritis measured according to Sharp’s method (van der Heijde modification). J Rheumatol 1995; 22(9): 1792–6

    PubMed  Google Scholar 

  84. Schiff MH, Yu EB, Weinblatt ME, et al. Long-term experience with etanercept in the treatment of rheumatoid arthritis in elderly and younger patients: patient-reported outcomes from multiple controlled and open-label extension studies. Drugs Aging 2006; 23(2): 167–78

    Article  PubMed  CAS  Google Scholar 

  85. Keystone EC, Schiff MH, Kremer JM, et al. Once-weekly administration of 50mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, doubleblind, placebo-controlled trial. Arthritis Rheum 2004; 50(2): 353–63

    Article  PubMed  CAS  Google Scholar 

  86. Lee H, Kimko HC, Rogge M, et al. Population pharmacokinetic and pharmacodynamic modeling of etanercept using logistic regression analysis. Clin Pharmacol Ther 2003; 73(4): 348–65

    Article  PubMed  CAS  Google Scholar 

  87. Moreland LW, Margolies G, Heck LW Jr, et al. Recombinant soluble tumor necrosis factor receptor (p80) fusion protein: toxicity and dose finding trial in refractory rheumatoid arthritis. J Rheumatol 1996; 23(11): 1849–55

    PubMed  CAS  Google Scholar 

  88. Mease PJ, Kivitz AJ, Burch FX, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 2004; 50(7): 2264–72

    Article  PubMed  CAS  Google Scholar 

  89. Ehlers S. Tumor necrosis factor and its blockade in granulomatous infections: differential modes of action of infliximab and etanercept? Clin Infect Dis 2005; 41Suppl. 3: S199–203

    Article  PubMed  CAS  Google Scholar 

  90. Ehlers S. Why does tumor necrosis factor targeted therapy reactivate tuberculosis? J Rheumatol Suppl 2005; 74: 35–9

    PubMed  CAS  Google Scholar 

  91. Keane J. TNF-blocking agents and tuberculosis: new drugs illuminate an old topic. Rheumatology (Oxford) 2005; 44(6): 714–20

    Article  CAS  Google Scholar 

  92. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001; 345(15): 1098–104

    Article  PubMed  CAS  Google Scholar 

  93. Sukal SA, Nadiminti L, Granstein RD. Etanercept and demyelinating disease in a patient with psoriasis. J Am Acad Dermatol 2006; 54(1): 160–4

    Article  PubMed  Google Scholar 

  94. Enayati PJ, Papadakis KA. Association of anti-tumor necrosis factor therapy with the development of multiple sclerosis. J Clin Gastroenterol 2005; 39(4): 303–6

    Article  PubMed  Google Scholar 

  95. Thomas CW Jr, Weinshenker BG, Sandborn WJ. Demyelination during anti-tumor necrosis factor alpha therapy with infliximab for Crohn’s disease. Inflamm Bowel Dis 2004; 10(1): 28–31

    Article  PubMed  Google Scholar 

  96. Chung ES, Packer M, Lo KH, et al. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the antiTNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 2003; 107(25): 3133–40

    Article  PubMed  CAS  Google Scholar 

  97. Anker SD, Coats AJ. How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH. Int J Cardiol 2002; 86(2–3): 123–30

    Article  PubMed  Google Scholar 

  98. Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006; 295(19): 2275–85

    Article  PubMed  CAS  Google Scholar 

  99. National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER) Program Public-Use Data (1973–1999) [11 Registries, 1992–1999]. Released April 2002, based on the November 2001 submission. Bethesda (MD): DCCPS, Surveillance Research Program, Cancer Statistics Branch, 2002

    Google Scholar 

  100. Fleischmann RM. Comparison of the efficacy of biologic therapy for rheumatoid arthritis: can the clinical trials be compared accurately? Rheum Dis Clin 2006; 1(3): 2–9

    Google Scholar 

Download references

Acknowledgements

No sources of funding were used to assist in the preparation of this review. Dr Roy Fleischmann has acted as a consultant for and received honoraria and grants from Amgen, Wyeth, Centocor and Abbott. Dr Imran Iqbal has no conflicts of interest that are directly relevant to the content of this review.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Roy Fleischmann.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fleischmann, R., Iqbal, I. Risk: Benefit Profile of Etanercept in Elderly Patients with Rheumatoid Arthritis, Ankylosing Spondylitis or Psoriatic Arthritis. Drugs Aging 24, 239–254 (2007). https://doi.org/10.2165/00002512-200724030-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-200724030-00005

Keywords

Navigation